Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
The return on equity (ROE) is N/A as of the fiscal period ended Tuesday, September 30, 2025.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q3 FY2025 (2025-09-30): -240.63%.
RETURN ON EQUITY (ROE)
N/A
RETURN ON EQUITY (ROE) AVG TTM
N/A
RETURN ON EQUITY (ROE) AVG 3Y
-213.69%
RETURN ON EQUITY (ROE) AVG 5Y
-106.00%
RETURN ON EQUITY (ROE) AVG 10Y
-48.99%
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Evogene Ltd.
Market Cap
$3.55M
Return on Equity (ROE)
N/A
TTM Avg
N/A
3Y Avg
-213.69%
5Y Avg
-106.00%
Market Cap
$3.49M
Return on Equity (ROE)
-40.20%
TTM Avg
193.27%
3Y Avg
-10433.46%
5Y Avg
-6975.64%
Market Cap
$3.57M
Return on Equity (ROE)
-591.60%
TTM Avg
-213.16%
3Y Avg
-150.57%
5Y Avg
-4.48%
Market Cap
$3.39M
Return on Equity (ROE)
-89.85%
TTM Avg
30.83%
3Y Avg
-183.24%
5Y Avg
-146.59%
Market Cap
$3.27M
Return on Equity (ROE)
-133.43%
TTM Avg
-203.84%
3Y Avg
-174.81%
5Y Avg
-140.61%
Market Cap
$3.59M
Return on Equity (ROE)
-383.03%
TTM Avg
-1602.50%
3Y Avg
-1094.59%
5Y Avg
-783.90%
Market Cap
$3.26M
Return on Equity (ROE)
-282.13%
TTM Avg
-313.25%
3Y Avg
-153.55%
5Y Avg
-153.55%
Market Cap
$3.23M
Return on Equity (ROE)
-40.75%
TTM Avg
-35.89%
3Y Avg
-218.64%
5Y Avg
-156.11%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Evogene Ltd. (EVGN) | $3.55M | N/A | N/A | -213.69% | -106.00% |
| Mustang Bio, Inc. (MBIO)vs › | $3.49M | -40.20% | 193.27% | -10433.46% | -6975.64% |
| Nexalin Technology, Inc. (NXL)vs › | $3.57M | -591.60% | -213.16% | -150.57% | -4.48% |
| Eocene Ltd. (EOCN)vs › | $3.48M | N/A | N/A | N/A | N/A |
| Moolec Science S.A. (MLEC)vs › | $3.39M | -89.85% | 30.83% | -183.24% | -146.59% |
| Aethlon Medical, Inc. (AEMD)vs › | $3.27M | -133.43% | -203.84% | -174.81% | -140.61% |
| Ernexa Therapeutics Inc. (ERNA)vs › | $3.59M | -383.03% | -1602.50% | -1094.59% | -783.90% |
| Cadrenal Therapeutics, Inc. Common Stock (CVKD)vs › | $3.26M | -282.13% | -313.25% | -153.55% | -153.55% |
| Paranovus Entertainment Technology Ltd. (PAVS)vs › | $3.23M | -40.75% | -35.89% | -218.64% | -156.11% |
| MBody AI Ltd. (MBAI)vs › | $3.16M | 120.45% | 927.43% | 433.61% | 340.10% |
ROE
N/A
ROA
-67.5%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2025-09-30 | -240.63% |
| 2024-06-30 | -647.77% |
| 2024-03-31 | -259.03% |
| 2023-12-31 | -198.12% |
| 2023-09-30 | -109.54% |
| 2023-06-30 | -159.83% |
| 2023-03-31 | -111.52% |
| 2022-12-31 | -95.37% |
| 2022-09-30 | -101.42% |
| 2022-06-30 | -86.81% |
| 2022-03-31 | -64.72% |
| 2021-12-31 | -51.80% |
| 2021-09-30 | -47.03% |
| 2021-06-30 | -38.73% |
| 2021-03-31 | -33.20% |
| 2020-12-31 | -50.76% |
| 2020-09-30 | -47.47% |
| 2020-06-30 | -52.25% |
| 2020-03-31 | -46.91% |
| 2019-12-31 | -36.12% |
| 2019-09-30 | -31.80% |
| 2019-06-30 | -43.22% |
| 2019-03-31 | -41.01% |
| 2018-12-31 | -41.47% |
| 2018-09-30 | -38.16% |
| 2018-06-30 | -35.70% |
| 2018-03-31 | -33.22% |
| 2017-12-31 | -30.04% |
| 2017-09-30 | -28.34% |
| 2017-06-30 | -26.91% |
| 2017-03-31 | -25.29% |
| 2016-12-31 | -22.44% |
| 2016-09-30 | -19.75% |
| 2016-06-30 | -17.08% |
| 2016-03-31 | -16.95% |
| 2015-12-31 | -16.59% |
| 2015-09-30 | -15.32% |
| 2015-06-30 | -15.73% |
| 2015-03-31 | -13.72% |
| 2014-12-31 | -12.52% |
| 2014-09-30 | -11.58% |
| 2014-06-30 | -9.89% |
| 2014-03-31 | -8.66% |
| 2013-12-31 | -7.12% |
| 2013-09-30 | -11.69% |
| 2013-06-30 | -8.77% |
| 2013-03-31 | -7.13% |
